The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 601–700 of 1,000
A simple and sensitive ‘in-house’ method for determining genotypic drug resistance in HIV-1
Lindström, A., & Albert, J. (2003) · Journal of Virological Methods · doi:10.1016/s0166-0934(02)00188-x · Cited by 36
Anti-HIV-1 Activity of Recombinant and Hybrid Species of Interferon-α
Sperber, S. J., Gocke, D. J., Haberzettl, C. A., Kuk, R., Schwartz, B., & Pestka, S. (1992) · Journal of Interferon Research · doi:10.1089/jir.1992.12.363 · Cited by 36
Nguyen, B., Shay, L., Wyvill, K. M., Pluda, J. M., Brawley, O. W., Cohen, R. B., Whitcup, S. M., Venzon, D. J., Broder, S., & Yarchoan, R. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.4.810 · Cited by 36
Antiviral Therapy in Human Immunodeficiency Virus Infections: Current Status (Part II)†
Sandström, E., & Öberg, B. F. (1993) · Drugs · doi:10.2165/00003495-199345050-00002 · Cited by 36
Latham, G. J., & Lloyd, R. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61933-2 · Cited by 36
The ethics of screening for early intervention in HIV disease.
Levine, C., & Bayer, R. (1989) · American Journal of Public Health · doi:10.2105/ajph.79.12.1661 · Cited by 36
Frissen, P. H. J., van der Ende, M. E., ten Napel, C. H. H., Weigel, H. M., Schreij, G., Kauffmann, R. H., Koopmans, P. P., Hoepelman, A. I. M., de Boer, J. B., Weverling, G. J., et al. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.6.1351 · Cited by 36
Orr, D., FIGUEIREDO, H., Mo, C. L., Penn, C. R., & Cameron, J. M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50645-7 · Cited by 36
Lori, F., HALL, L., Lusso, P., Popovic, M., Markham, P. D., Franchini, G., & Reitz, M. S. (1992) · Journal of Virology · doi:10.1128/jvi.66.9.5553-5560.1992 · Cited by 36
Curiel, T. J., Cook, D. R., Wang, Y., Hahn, B. H., Ghosh, S. K., & Harrison, G. S. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.6-741 · Cited by 36
Anand, R., Nayyar, S., Galvin, T. A., Merril, C. R., & Bigelow, L. B. (1990) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1990.6.679 · Cited by 36
Vaidya, N. K., & Rong, L. (2017) · SIAM Journal on Applied Mathematics · doi:10.1137/16m1092003 · Cited by 35
Loya, S., Rudi, A., Kashman, Y., & Hizi, A. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3620685 · Cited by 35
BRIDGES, C. G., Brennan, T., Taylor, D. L., McPherson, M., & Tyms, A. S. (1994) · Antiviral Research · doi:10.1016/0166-3542(94)90105-8 · Cited by 35
Wang, X., Douglas, S. D., Lai, J.-P., Tuluc, F., Tebas, P., & Ho, W. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9059-6 · Cited by 35
Smith, R. A., Remington, K. M., Preston, B. D., Schinazi, R. F., & North, T. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2335-2340.1998 · Cited by 35
Discovery and in Vitro Development of AIDS Antiviral Drugs as Biopharmaceuticals
Rice, W. G., & Bader, J. P. (1995) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60675-4 · Cited by 35
Therapeutic Drug Monitoring and Human Immunodeficiency Virus (HIV) Antiretroviral Therapy
Justesen, U. S. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_246.x · Cited by 35
Persistent herpes simplex virus infection and mechanisms of virus drug resistance
Field, H. J. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963751 · Cited by 35
The Emergence and Epidemiology of Resistance in the Nucleoside-Experienced HIV-Infected Population
Pillay, D. (2001) · Antiviral Therapy · doi:10.1177/135965350100603s02 · Cited by 35
Inhibitory RNA Ligand to Reverse Transcriptase from Feline Immunodeficiency Virus
Chen, H., McBroom, D. G., Zhu, Y.-Q., Gold, L., & North, T. W. (1996) · Biochemistry · doi:10.1021/bi9600106 · Cited by 35
Fontenot, G. K., Johnston, K. H., Cohen, J., Gallaher, W. R., Robinson, J. E., & Luftig, R. B. (1992) · Virology · doi:10.1016/0042-6822(92)91186-x · Cited by 35
Peter, K., & Gambertoglio, J. G. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90132-0 · Cited by 35
Bakshi, S. S., Britto, P., Capparelli, E. V., MOFENSON, L. M., Fowler, M. G., Rasheed, S., Schoenfeld, D., Zimmer, B., Frank, Y., Yogev, R., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/520351 · Cited by 35
Cleland, A., Watson, H. G., Robertson, P., Ludlam, C. A., & Brown, A. (1996) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199605010-00002 · Cited by 35
Imrie, A. A., Carr, A., Duncombe, C. J., Finlayson, R. J., Vizzard, J., Law, M. G., Kaldor, J. M., Penny, R., Cooper, D. A., & the Sydney Primary HIV Infection Study Group (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.1.195 · Cited by 35
Belay, W. Y., Getachew, M., Tegegne, B. A., Teffera, Z. H., Dagne, A., Zeleke, T. K., Wondm, S. A., Abebe, R. B., Gedif, A. A., Fenta, A., et al. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251340144 · Cited by 34
Pandit, A., Mackay, W. G., Steel, C., van Loon, A. M., & Schuurman, R. (2008) · Journal of Clinical Virology · doi:10.1016/j.jcv.2008.08.021 · Cited by 34
Kim, H. W., Shim, M. J., Choi, E. C., & Kim, B. K. (1997) · Archives of Pharmacal Research · doi:10.1007/bf02973934 · Cited by 34
Therapy of HIV Infection: Current Approaches and Prospects
Prokofjeva, M. M., Kochetkov, S. N., & Prassolov, V. (2016) · Acta Naturae · doi:10.32607/20758251-2016-8-4-23-32 · Cited by 34
Smith, R. A., Remington, K. M., Lloyd, R. M., Schinazi, R. F., & North, T. W. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.2357-2362.1997 · Cited by 34
Hales, G., Birch, C. J., Crowe, S., Workman, C., Hoy, J., Law, M. G., Kelleher, A. D., Lincoln, D. J., & Emery, S. (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010018 · Cited by 34
Jones‐Brando, L. V., Buthod, J. L., Holland, L. E., Yolken, R. H., & Torrey, E. F. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00007-8 · Cited by 34
Wang, J., Jin, Y., Rapp, K. L., Bennett, M. S., Schinazi, R. F., & Chu, C. K. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050096d · Cited by 34
Lerma, J. G. G., Schinazi, R. F., Juodawlkis, A. S., Soriano, V., Lin, Y., Tatti, K. M., Rimland, D., Folks, T. M., & Heneine, W. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.264 · Cited by 34
Drusano, G. L., Yuen, G. J., Morse, G. D., Cooley, T. P., Seidlin, M., Lambert, J. S., Liebman, H. A., Valentine, F. T., & Dolin, R. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.6.1280 · Cited by 34
Antiviral Synergy between Inhibitors of HIV Proteinase and Reverse Transcriptase
Craig, J. C., Duncan, I. B. R., Whittaker, L., & Roberts, N. A. (1993) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029300400305 · Cited by 34
Naesens, L. M. J., Balzarini, J. M., & Clercq, E. D. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90058-y · Cited by 34
Craig, J. C., Whittaker, L., Duncan, I. B. R., & Roberts, N. A. (1993) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029300400605 · Cited by 34
Liu, H., Li, Z., Reindl, T., He, Z., Qiu, X., Golden, R. P., Donovan, K. A., Bailey, A. L., Fischer, E. S., Zhang, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49161-9 · Cited by 33
Lai, C.-C., Hung, C., Chen, M.-Y., Sun, H., Lu, C.-L., Tseng, Y.-T., Chang, S.-F., Su, Y., Liu, W., Hsieh, C.-Y., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr601 · Cited by 33
Rideout, D. C., Schinazi, R. F., Pauza, C. D., Lovelace, K., Chiang, L., Calogeropoulou, T., McCarthy, M., & Elder, J. H. (1993) · Journal of Cellular Biochemistry · doi:10.1002/jcb.2400510410 · Cited by 33
Ramezani, A., & Joshi, S. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.229 · Cited by 33
Gopalakrishnan, V., & Benkovic, S. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41750-9 · Cited by 33
Hostetler, K. Y., Richman, D. D., Carson, D. A., Stuhmiller, L. M., van Wijk, G. M. T., & van den BOSCH, H. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.2025 · Cited by 33
Self-citationLund, O., Lund, O., Gram, G. J., Nielsen, S. D., Schønning, K., Nielsen, J. O., Hansen, J. S., & Mosekilde, E. (1997) · Bulletin of Mathematical Biology · doi:10.1007/bf02458427 · Cited by 33
Rigourd, M., Ehresmann, C., Parniak, M. A., Ehresmann, B., & Marquet, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110836200 · Cited by 33
Kim, E., Vrang, L., Öberg, B. F., & Merigan, T. C. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201750102445 · Cited by 33
Combined zidovudine and interferon‐alpha treatment in patients with AIDS‐associated Kaposi's sarcoma
de Wit, R., Danner, S. A., Bakker, P. J. M., Lange, J. M. A., Schattenkerk, J. K. M. E., & Veenhof, C. H. N. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00303.x · Cited by 33
Rey, D., Hughes, M. D., Pi, J.-T., Winters, M. A., Merigan, T. C., & Katzenstein, D. A. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199803010-00003 · Cited by 33
Torres, J. V., Malley, A., Banapour, B., Anderson, D. E., Axthelm, M. K., Gardner, M. B., & Benjamini, E. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.423 · Cited by 33
IVES, K. J., Jacobsen, H., Galpin, S. A., Garaev, M. M., Dorrell, L., Mous, J., Bragman, K., & Weber, J. N. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/39.6.771 · Cited by 33
Miller, M. D., Margot, N., Lamy, P. D., Fuller, M. D., Anton, K. E., Mulato, A. S., & Cherrington, J. M. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200108150-00005 · Cited by 33
Exploiting Genetic Interference for Antiviral Therapy
Tanner, E. J., Kirkegaard, K., & Weinberger, L. S. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005986 · Cited by 32
Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.
Pincus, S. H., Wehrly, K., Tschachler, E., Hayes, S. F., Buller, R. S., & Reitz, M. S. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.3.745 · Cited by 32
Burnett, B. P., & McHenry, C. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7210 · Cited by 32
THE HUMAN IMMUNODEFICIENCY VIRUS
Hardy, W. D. (1996) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70489-2 · Cited by 32
Kew, Y., Qingbin, S., & Prasad, V. R. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36610-3 · Cited by 32
Challenges in the therapy of HIV infection
Yarchoan, R., Mitsuya, H., & Broder, S. E. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90050-u · Cited by 32
Rhodes, R. H. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90215-3 · Cited by 32
Eron, J. J., Gorczyca, P., Kaplan, J. C., & D’Aquila, R. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3241 · Cited by 32
The clarifying role of time series data in the population genetics of HIV
Feder, A. F., Pennings, P. S., & Petrov, D. A. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009050 · Cited by 31
Stürmer, M., Berger, A., & Doerr, H.-W. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10527 · Cited by 31
Ntemgwa, M. L., Toni, T. D., BRENNER, B. G., Oliveira, M., Asahchop, E. L., Moisi, D. D., & Wainberg, M. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01109-08 · Cited by 31
Remington, K. M., Zhu, Y. Q., Phillips, T. R., & North, T. W. (1994) · Journal of Virology · doi:10.1128/jvi.68.2.632-637.1994 · Cited by 31
Ingenol Derivatives are Highly Potent and Selective Inhibitors of HIV Replication in Vitro
Fujiwara, M., Ijichi, K., Tokuhisa, K., Katsuura, K., Wang, G.-Y.-S., Uemura, D., Shigeta, S., Konno, K., Yokota, T., & Baba, M. (1996) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029600700502 · Cited by 31
HIV‐1 Protease inhibitors: Their development, mechanism of action and clinical potential
Pillay, D., Bryant, M. L., Getman, D. P., & Richman, D. D. (1995) · Reviews in Medical Virology · doi:10.1002/rmv.1980050104 · Cited by 31
Self-citationRichman, D. D. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90619-x · Cited by 31
Self-citationWinters, M. A., Coolley, K. L., Peng, C., Girard, Y. A., Hamdan, H. B., Kovari, L. C., & Merigan, T. C. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10707-10713.2000 · Cited by 31
Redshaw, S. D. (1994) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.3.3.273 · Cited by 31
Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia
Hoare, A., Kerr, S. J., Ruxrungtham, K., Ananworanich, J., Law, M. G., Cooper, D. A., Phanuphak, P., & Wilson, D. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010981 · Cited by 30
Anti-herpetic activity of various medicinal plant extracts
Woo, E., Kim, H. J., Kwak, J. H., Lim, Y. K., Park, S. K., Kim, H. S., Lee, C.-K., & Park, H. (1997) · Archives of Pharmacal Research · doi:10.1007/bf02974043 · Cited by 30
Chapter 13. Advances in the Development of HIV Reverse Transcriptase Inhibitors
Romero, D. L. (1994) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60726-5 · Cited by 30
Pharmacokinetics of antiviral polyoxometalates in rats
Ni, L., Boudinot, F. D., Boudinot, S. G., Henson, G., Bossard, G. E., Martellucci, S. A., Ash, P. W., Fricker, S. P., Darkes, M. C., & Theobald, B. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.504 · Cited by 30
Clementi, M., Menzo, S., BAGNARELLI, P., Valenza, A., Paolucci, S., Sampaolesi, R., Manzin, A., & Varaldo, P. E. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.2.135 · Cited by 30
Miller, M. D., Lamy, P. D., Fuller, M. D., Mulato, A. S., Margot, N., Cihlář, T., & Cherrington, J. M. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.2.291 · Cited by 30
Skowron, G., & Merigan, T. C. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90417-c · Cited by 30
Wahlberg, J., Fiore, J. R., Angarano, G., Uhlén, M., & Albert, J. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.3.611 · Cited by 30
Terrett, N. T., Bojanic, D., Merson, J. R., & Stephenson, P. T. (1992) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)80468-0 · Cited by 30
Tanaka, M., Srinivas, R. V., Ueno, T., Kavlick, M. F., Hui, F. K., Fridland, A., Driscoll, J. S., & Mitsuya, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1313 · Cited by 30
Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science
Saag, M. S. (2022) · Physiological Reviews · doi:10.1152/physrev.00010.2022 · Cited by 30
Drug Delivery through Phagocytosis of Red Blood Cells
Serafini, S., Rossi, L., Antonelli, A., Fraternale, A., Cerasi, A., Crinelli, R., Chiarantini, L., Schiavano, G. F., & Magnani, M. (2004) · Transfusion Medicine and Hemotherapy · doi:10.1159/000078042 · Cited by 29
Effects of incarceration on HIV-infected individuals.
Griffin, M. M., Ryan, J., Briscoe, V. S., & Shadle, K. M. (1996) · PubMed · Cited by 29
Tewari, D., Goldstein, S. L., Notkins, A. L., & Zhou, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2642 · Cited by 29
Klopman, G., & Tu, M. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980451i · Cited by 29
Intramuscular anti‐D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura
Gringeri, A., Cattaneo, M., Santagostino, E., & Mannucci, P. M. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08142.x · Cited by 29
Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance
Puchhammer-St�ckl, E., Schmied, B., Mandl, C. W., Vetter, N., & Heinz, F. X. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199903)57:3<283::aid-jmv12>3.0.co;2-2 · Cited by 29
Clinical applications of 3′‐azido‐2′,3′‐ dideoxythymidine (AZT) and related dideoxynucleosides
Broder, S. E. (1990) · Medicinal Research Reviews · doi:10.1002/med.2610100403 · Cited by 29
Daar, E. S., Chernyavskiy, T., ZHAO, J.-Q., Krogstad, P. A., Chen, I. S. Y., & Zack, J. A. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.3 · Cited by 29
Nucleoside Reverse Transcriptase Inhibitors And Resistance Of Human Immunodeficiency Virus Type 1
Johnson, V. A. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_2.s140 · Cited by 29
Mazzulli, T., Rusconi, S., Merrill, D. P., D’Aquila, R. T., Moonis, M., Chou, T., & Hirsch, M. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.656 · Cited by 29
Valentine, F. T., Seidlin, M., Höchster, H. S., & Laverty, M. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_5.s534 · Cited by 29
DIANZANI, F., Antonelli, G., Turriziani, O., Riva, E., Dong, G., & Bellarosa, D. (1993) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029300400604 · Cited by 29
Turk, G., Moroni, G. N., Pampuro, S. E., Briñón, M. C., & Salomón, H. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00191-7 · Cited by 28
Royer, R. E., Mills, R. G., Young, S. A., & Jagt, D. L. V. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80047-6 · Cited by 28
Sowell, R. L., Phillips, K. D., & Grier, J. E. C. (1998) · AIDS Patient Care and STDs · doi:10.1089/apc.1998.12.33 · Cited by 28
Palmer, D. L., Hjelle, B. L., Wiley, C. A., Allen, S., Wachsman, W., Mills, R., Davis, L. E., & Merlin, T. L. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90012-4 · Cited by 28
Antiviral resistance in clinical practice
Kimberlin, D. W., Crumpacker, C. S., Straus, S. E., Biron, K. K., Drew, W., Hayden, F. G., McKinlay, M. A., Richman, D. D., & Whitley, R. J. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00031-g · Cited by 28
Self-citationThe Role of Antiretrovirals and Drug Resistance in Vertical Transmission of HIV‐1 Infection
BRENNER, B. G., & Wainberg, M. A. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05467.x · Cited by 28
Antonucci, T. K., Warmus, J. S., Hodges, J. C., & Nickell, D. G. (1995) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029500600204 · Cited by 28
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.